secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2025-04-08T23:59:59+00:00
Accession:  0001193125-25-075871
Event type: litigation
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma to pay $145M to settle Xyrem antitrust class action; records Q1 charge
--------------------------------------------------------------------------------

- Jazz Pharmaceuticals Ireland subsidiary agrees to pay $145M lump sum to settle indirect Xyrem purchaser class action.
- Company will record a pre-tax charge of approximately $145M in Q1 2025, funded by cash on hand.
- Settlement remains subject to court approval; Jazz denies all alleged wrongdoing.
- The settlement resolves the majority of claims in the multi-district litigation; additional settlements with remaining plaintiffs may be significant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312525075871/0001193125-25-075871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312525075871/d901769d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-075871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer